Main menu

Pages

Clinical Testing of the cAd3-Ebola and MVA-EbolaZ vaccines

Clinical Testing of the cAd3-Ebola and MVA-EbolaZ vaccines In two parallel phase I/Ib trials, both cAd3-vectored Ebola and MVA-EbolaZ vaccines were safe and well tolerated in healthy adults recruited from the United States and Uganda. The vaccines were immunogenic and elicited durable antibody responses.

Comments

Titles